Royal Arc Electrodes IPO GMP trend is as follows: On 24 February 2025, the IPO price was ₹120, with a GMP of ₹0. The estimated listing price was ₹120.00.
**The GMP prices shown here are only news related to the grey market. We do not trade/deal in grey market or subject to rates (sub2), nor do we recommend trading in grey market.
GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Estimated Listing Price | Last Updated |
|---|---|---|---|---|---|
| 24 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-24 09:40:00 AM |
| 21 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-21 08:29:00 AM |
| 20 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-20 10:31:00 AM |
| 18 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-18 01:54:00 PM |
| 17 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-17 01:59:00 PM |
| 13 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-13 11:58:00 AM |
| 12 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-12 03:35:00 PM |
| 11 Feb 25 | ₹120 | ₹0 | -- | ₹120 | 2025-02-11 05:01:00 PM |
The grey market premium (GMP) is the price at which an IPO is traded unofficially before it is listed. This premium provides an indication of how the market might react to a particular company's IPO on its first day of trading. A positive GMP suggests the IPO is likely to debut at a gain, while a negative GMP indicates it could open at a discount.
It is important to remember that the IPO GMP is highly volatile, so relying solely on the Royal Arc Electrodes IPO GMP for an investment decision is risky. Therefore, before investing in the Royal Arc Electrodes IPO, you should take all factors into account to make a well-informed decision.
DISCLAIMER: The financial details provided here are for educational purposes only and should not be seen as a recommendation to buy or sell securities. This content is not a substitute for professional investment advice. Before making any investment decisions, you must consult with a qualified financial advisor. Any investment decisions made based on this information are at your own risk. Be aware that investing in the stock market involves unpredictable risks. The author has no intention of investing in this offering.